A Word to the Wise About Intranasal Esketamine
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Safety concerns attributable to long-term ketamine/esketamine exposure include potential for abuse and misuse, tolerance and withdrawal, effects on liver function, and possibly kidney and/or urogenital toxicity.
“Safety concerns attributable to long- term ketamine/esketamine exposure include potential for abuse and misuse, tolerance and withdrawal, effects on liver function, and possibly kidney and/or urogenital toxicity 206 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [206]
The main text (page unavailable) identifies ketamine’s abusability and raises possible tolerance and withdrawal concerns with longer-term use, while noting uncertainty about tolerance during intermittent use. It does not address liver function or kidney or urogenital toxicity, so those parts of the attributed claim are unsupported. (LLM, conf=0.88)
Experimental — accuracy not yet measuredThe three suicides occurred 4, 12, and 20 days after the last dose of esketamine.
“The three suicides occurred in participants 4, 12 and 20 days after the last dose of esketamine.26”
From Are we repeating mistakes of the past? A review of the evidence for esketamine (2021) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 9 · Cited by 96
- Authors
- Schatzberg, A. F.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Schatzberg, Alan F.
- ORCID
- Schatzberg, Alan F.
- Venue
- American Journal of Psychiatry
- Published
- 2019-06-01
- Volume
- 176
- Issue
- 6
- Pages
- 422-424
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2946621262
- Cited by
- 96
- References
- 9
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 12 · 2023: 5 · 2022: 16 · 2021: 18 · 2020: 20 · 2019: 9
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- esketamine, intranasal administration, ketamine, depression treatment
- MeSH terms
- Administration, Intranasal, Antidepressive Agents, Depression, Double-Blind Method, Ketamine, Nasal Sprays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
